EdgeScore

MTNB · NYSE

Matinas BioPharma Holdings, Inc.: financial statements

Financially weak · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2018: $120KNet income 2018: -$14.1M2018Revenue 2019: $89.8KNet income 2019: -$17.4M2019Revenue 2020: $158KNet income 2020: -$22.4M2020Revenue 2021: $33.0KNet income 2021: -$23.3M2021Revenue 2022: $3.2MNet income 2022: -$21.0M2022Revenue 2023: $1.1MNet income 2023: -$22.9M2023
RevenueNet income

Operating and free cash flow

Operating cash flow 2018: -$10.3MFree cash flow 2018: -$10.9M2018Operating cash flow 2019: -$14.1MFree cash flow 2019: -$14.5M2019Operating cash flow 2020: -$17.4MFree cash flow 2020: -$17.4M2020Operating cash flow 2021: -$15.2MFree cash flow 2021: -$15.5M2021Operating cash flow 2022: -$19.2MFree cash flow 2022: -$20.0M2022Operating cash flow 2023: -$15.3MFree cash flow 2023: -$15.5M2023
Operating cash flowFree cash flow

Margins

Operating 2018: -12230.9%Operating 2019: -21067.4%Operating 2020: -15288.4%Operating 2021: -74954.5%Operating 2022: -771.3%Operating 2023: -2168.4%Net 2018: -11760.4%Net 2019: -19343.4%Net 2020: -14177.0%Net 2021: -70554.5%Net 2022: -658.6%Net 2023: -2093.2%201820192020202120222023
GrossOperatingNet

Returns

ROE 2018: -87.2%ROE 2019: -52.6%ROE 2020: -35.2%ROE 2021: -44.4%ROE 2022: -57.3%ROE 2023: -119.2%ROIC 2018: -313.2%ROIC 2019: -205.1%ROIC 2020: -61.5%ROIC 2021: -47.2%ROIC 2022: -63.4%ROIC 2023: -84.8%ROA 2018: -70.6%ROA 2019: -43.2%ROA 2020: -31.6%ROA 2021: -38.0%ROA 2022: -46.8%ROA 2023: -91.4%201820192020202120222023
ROEROICROA

Income statement

USD201820192020202120222023Last year
Revenue$120K$89.8K$158K$33.0K$3.2M$1.1M-66%
Operating income-$14.6M-$18.9M-$24.2M-$24.7M-$24.6M-$23.8M+3%
EBITDA-$14.4M-$18.7M-$24.0M-$24.5M-$24.3M-$23.4M+4%
Profit before tax—————-$22.9M
Income tax$507K—————
Net income-$14.1M-$17.4M-$22.4M-$23.3M-$21.0M-$22.9M-9%

Cash flow

USD201820192020202120222023Last year
Operating cash flow-$10.3M-$14.1M-$17.4M-$15.2M-$19.2M-$15.3M+20%
Capital expenditure$536K$406K$5.7K$260K$892K$218K-76%
Free cash flow-$10.9M-$14.5M-$17.4M-$15.5M-$20.0M-$15.5M+23%
Depreciation & amortization$218K$206K$231K$244K$337K$385K+14%

Balance sheet

USD201820192020202120222023Last year
Cash$12.4M$22.2M$12.4M$21.0M$6.8M$4.8M-30%
Current assets$13.1M$29.9M$61.6M$51.0M$34.5M$15.5M-55%
Total assets$19.9M$40.2M$71.0M$61.3M$44.8M$25.1M-44%
Current liabilities$2.8M$3.1M$3.6M$4.3M$4.3M$2.6M-39%
Total liabilities$3.8M$7.2M$7.2M$8.8M$8.2M$5.9M-28%
Shareholders' equity$16.1M$33.1M$63.7M$52.5M$36.6M$19.2M-47%
Net debt-$12.4M-$22.2M-$12.4M-$21.0M-$6.8M-$4.8M+30%

Ratios

201820192020202120222023Last year
Operating margin-12230.9%-21067.4%-15288.4%-74954.5%-771.3%-2168.4%
Net margin-11760.4%-19343.4%-14177.0%-70554.5%-658.6%-2093.2%
Return on equity-87.2%-52.6%-35.2%-44.4%-57.3%-119.2%
Return on assets-70.6%-43.2%-31.6%-38.0%-46.8%-91.4%
Return on invested capital-313.2%-205.1%-61.5%-47.2%-63.4%-84.8%
Current ratio4.619.6617.2511.738.065.93
Quick ratio4.619.6617.2511.738.065.93

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.